About this bibliography
An annotated reading of the peptide literature. Not a clinic, not a vendor, not a recommendation engine.
What this bibliography is
Peptide Research Alliance is an annotated bibliography of the five research peptides people ask about most: Retatrutide, BPC-157, Ipamorelin, PT-141, and NAD+. The aim is one dependable place where somebody who has run into one of these compounds — in a health context or a research one — can quickly grasp what it is, how it works, and what the published evidence actually says, without picking through promotional copy, vendor landing pages, or community threads that fold real findings into wishful thinking.
Each entry is a headnote over a reading list. The writing is done by people who work in science communication, and every substantive claim carries a citation to a publicly accessible source — PubMed, ClinicalTrials.gov, peer-reviewed journals, FDA prescribing information. Where the evidence is thin, the annotation says so; where it is strong, it says that too.
How each entry is annotated
What gets read: peer-reviewed clinical trials, regulatory documents (FDA prescribing information, the WADA prohibited list), systematic reviews, and pharmacokinetic studies come first — ahead of observational reports, case studies, or conference abstracts. For community-reported effects (kept in a clearly labeled "anecdotal" section on each compound page), the source is accessible, publicly documented community discussion and published qualitative analysis.
How it is cited: every factual claim about a compound's mechanism, study finding, regulatory status, or safety caution names a specific source in the references. Nothing is paraphrased without attribution; nothing is carried from one species to another without flagging the jump; an animal finding is never dressed as human evidence.
Accuracy guards: each compound comes with its own compliance constraints — for instance, the informal label "GLP-3" is never applied to retatrutide (it is a misnomer in the scientific literature), PT-141's FDA-approved scope is stated as HSDD in premenopausal women only, and NAD+ is kept distinct from its precursors NMN and NR throughout.
Where the annotation ends: no dosing advice; no product or supplier recommendations; no financial tie to any vendor of any compound covered here; no sponsored content. Nothing on this site should be read as medical advice.
Standing and disclaimer
Peptide Research Alliance holds no commercial relationship with any manufacturer, supplier, or clinic dealing in the compounds covered here, and accepts no advertising that promotes the sale of research compounds or their precursors.
What you read is for information and education only — a summary of publicly available published research. It is not medical advice, not a clinical recommendation, and not a suggestion that anyone should use any compound described. Regulatory-status notes reflect publicly available sources as of their publication date and can change; readers should confirm current status themselves.
A researcher or clinician looking to access compounds for legitimate research or therapeutic use should consult the relevant regulatory bodies and follow the laws of their own jurisdiction.